Nusano News
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an...
Nusano to Host Radiopharmaceuticals Educational Webinar
EVENT REPLAY NOW AVAILABLE Recorded June 28, 2024Nusano and LifeSci Advisors invite you to go back to school... Join us on Friday, June 28, 2024 from 11:30 a.m. to 12:30 p.m. Eastern for Office Hours: Radiopharmaceuticals. This informative discussion will explain how...
Nusano to Present at Jefferies Radiopharma Innovation Summit
VALENCIA, Calif. – April 10, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024. In his presentation,...
Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress
Nusano will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24.
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration
Photo above: On Friday, March 8, 2024, representatives from Nusano and The Wasatch Group cut the ribbon on the Radiance Lab, a 5,000 square foot radiochemistry space that will develop radioisotope separation and purification processes for Nusano. (L-to-R) Howard...
Nusano to Participate in the B. Riley Securities Radiopharma Investor Conference
VALENCIA, Calif. – February 26, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will participate in a presentation and panel at the B. Riley Securities Radiopharma Investor Conference in New York City on...
Nusano Names Rohan Jain as Commercial General Manager
VALENCIA, Calif. – Jan. 22, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced Rohan Jain as its Commercial General Manager. Jain and his team will work with Nusano’s customers and prospects to assess their needs and...
Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics
EVENT REPLAY NOW AVAILABLE Recorded December 19, 2023Press release updated December 14, 2023 to include addition of Dr. OrozcoVALENCIA, Calif. – Dec. 12, 2023 – Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will...
Nusano to Participate in October Investor Conferences
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer
Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
Video Replay: Unlocking the Next $20-30B Market Opportunity in Oncology: Radioisotope Production & Applications
With many now expecting radiopharamaceuticals to grow into a $20-30 billion market, investors are increasingly looking at the obstacles and opportunities for suppliers and drugmakers in this space. To advance these discussions, on Friday, May 12, 2023, Nusano and...
BLOG Posts
MedicalXpress: Researchers develop new method of precisely targeting cancer lesions while protecting healthy tissues
From MedicalXpress: A team of researchers has developed a new method that suppresses the distribution of drugs to...
ICR: ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
Case Study: Radioisotope supply challenges affecting prostate cancer treatment
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates